U.S. Metals and Mining Stock News

Recent gains in Bicara Therapeutics (BCAX) stock have come alongside a series of fresh analyst updates, earnings results and clinical progress headlines that have sharpened attention on the company’s development pipeline. See our latest analysis for Bicara Therapeutics. The recent analyst upgrades and clinical updates have come alongside a clear build in momentum, with a 30 day share price return of 16.24% and a 1 year total shareholder return of 103.12% at a latest share price of $21.47. If...

Upwork (NasdaqGS:UPWK) is rolling out new AI driven features on its freelance platform, including its assistant Uma and expanded workforce management tools. The company is extending these capabilities across its marketplace to support both businesses and freelancers who rely on remote and project based work. The updates are part of an ongoing effort to integrate AI into talent discovery, project scoping, and ongoing engagement on the platform. For investors tracking online talent platforms,...

In March 2026, Worthington Enterprises, Inc. reported higher year-over-year third-quarter and nine-month sales and net income, continued its share repurchases, and its Board declared a US$0.19 per-share quarterly dividend payable on June 29, 2026. Together, the earnings growth, ongoing buybacks that have retired more than two-fifths of shares since 2014, and the uninterrupted dividend record since 1968 highlight the company’s long-running focus on returning cash to shareholders. Next, we’ll...

RCM Technologies (RCMT) has wrapped up FY 2025 with fourth quarter revenue of US$86.5 million, basic EPS of US$0.80 and net income of US$6.1 million. The trailing twelve months show revenue of US$319.4 million, EPS of US$2.19 and net income of US$16.3 million, with earnings growth of 22.4% over the past year. Over recent periods the company has seen revenue move from US$278.4 million to US$319.4 million on a trailing basis, alongside EPS shifting from US$1.72 to US$2.19. This ties into a net...

In recent months, Soleno Therapeutics has faced multiple securities class action lawsuits alleging that the company and certain executives failed to disclose material safety concerns and data integrity issues tied to the Phase 3 program for its Prader‑Willi syndrome drug DCCR, marketed as VYKAT XR. These legal challenges, centered on claims of undisclosed risks such as fluid retention, diabetes‑related markers, and high discontinuation rates, have intensified scrutiny of VYKAT XR’s clinical...

In recent days, Assured Guaranty director Francisco Borges sold 123,750 shares of the company, a transaction worth nearly US$9.93 million, marking a large reduction in his personal stake. This insider sale comes as Assured Guaranty balances strong profitability and a solid balance sheet with pressures from lower-yield AA business and its Assured Life Re annuity reinsurance expansion. We’ll now examine how Borges’ sizable insider sale could influence Assured Guaranty’s investment narrative,...

AI data centers, stubborn energy costs, and heightened geopolitical risk are all pushing reliable, carbon free power to the forefront of investment thinking. Nuclear sits at the center of that discussion, with governments, utilities, and large corporates all searching for 24/7 electricity that does not depend on weather or imported fossil fuels. Our Nuclear Renaissance screener is built to help you focus on listed companies most closely aligned with this long term trend. In this article, you...

Event context and recent price performance Minimed Group (MMED) has been in focus after recent share price weakness, with the stock down 3.2% over the past week and 24.2% year to date. This has prompted fresh attention on its fundamentals. The Northridge based diabetes technology company reports annual revenue of US$2,886 and a net loss of US$211. This places its current valuation of about US$3.9b under closer scrutiny among investors. See our latest analysis for Minimed Group. With the...

Global Payments' Link2Gov unit has been selected by the IRS as a preferred digital payments provider for the 2026 tax season. The mandate covers digital tax payments, highlighting Link2Gov's role in supporting federal e-payment capabilities. This selection places NYSE:GPN directly in the middle of U.S. government efforts to modernize tax collection systems. Global Payments, through its Link2Gov unit, is focused on digital payment processing across government and enterprise clients. Being...

For investors wondering if Turning Point Brands at around US$72.16 is still offering value or if the easy gains are behind it, this article focuses squarely on what the current price might be implying. The stock has pulled back sharply in the short term, with a 15.5% decline over the last 7 days and a 21.9% decline over the last 30 days, even though the 1 year return sits at 32.8% and the 3 year return is 254.2%. Recent market attention has centered on how this performance, including a year...

In late March 2026, Golar LNG Limited filed an omnibus shelf registration covering a broad range of securities and separately began a formal review of options such as a sale, merger, asset divestitures, or corporate structure changes to accelerate its Floating Liquefied Natural Gas (FLNG) growth plans. This combination of financing flexibility and a wide-ranging review of potential transactions highlights how Golar is reassessing how best to monetize its FLNG platform, long-term contract...

BlackSky Technology (NYSE:BKSY) received a sole source, multi year US$99 million IDIQ contract from the U.S. government. The award comes from the Air Force Research Laboratory and targets advanced optical payload and next generation space intelligence capabilities. The contract focuses on large aperture optical systems and AI enabled space data tools that differ from BlackSky's existing Gen 2 and Gen 3 offerings. For readers tracking NYSE:BKSY, this contract sits at the center of the...

Royalty Pharma (NasdaqGS:RPRX) has entered into a new R&D co-funding agreement with Johnson & Johnson to develop a novel autoimmune therapy. The company has also appointed a Head of Artificial Intelligence to expand the use of advanced analytics and data science across its operations. These announcements mark a shift toward greater involvement in drug development and data driven decision making. Royalty Pharma, known primarily for acquiring biopharma royalties, typically gives investors...

Regulators allowed the Hart Scott Rodino antitrust waiting period for Coterra Energy's merger with Devon Energy to expire, clearing a key hurdle. This approval means Coterra Energy (NYSE:CTRA) can move toward closing, with the company expected to become a wholly owned subsidiary of Devon. The companies currently anticipate closing the transaction in Q2 2026, subject to remaining customary conditions. Coterra Energy focuses on oil and gas exploration and production, an area where scale, cost...

Wix.com (NasdaqGS:WIX) completed a modified Dutch auction share repurchase, buying back nearly 30% of its outstanding shares. The buyback reduces Wix's share count and follows a period of increased focus on AI driven product investments. The transaction comes as some analysts lower their ratings on the stock, even as the company continues to invest in growth initiatives. Wix.com runs a global website creation and business management platform used by individuals, small businesses, and larger...

Executive change triggers fresh look at Ardent Health stock Ardent Health (ARDT) shares are in focus after the company announced that Ethan Chernin, President of Hospital Services, departed on March 24, 2026, under its executive severance plan, prompting investors to reassess leadership stability and valuation. See our latest analysis for Ardent Health. With the latest close at $8.66, Ardent Health has seen a 1 month share price return of 8.26% decline and a 1 year total shareholder return of...

Vontier Corporation recently entered into a 364-day senior unsecured term loan agreement for a US$300 million facility maturing on March 30, 2027, with interest tied to Term SOFR or a base rate plus ratings-based margins, to help repay 2026 senior unsecured notes and fund general corporate purposes. This short-term, unsecured financing underscores lenders’ confidence in Vontier’s credit profile while reshaping its near-term capital structure and liquidity position. We’ll now examine how...

National Presto Industries stock snapshot National Presto Industries (NPK) has quietly put up strong recent returns, with the stock up about 4.5% over the past month and roughly 32% over the past 3 months. See our latest analysis for National Presto Industries. That recent momentum sits on top of a strong longer run, with a 1 year total shareholder return of 73.12% and a 3 year total shareholder return of 117.67%. The share price is now at $141.65 after a 90 day share price return of...

AtriCure recently reported its fourth-quarter 2025 results, highlighting 15% revenue growth that underscored continued demand for its cardiac and pain management devices. The contrast between solid operating performance and more cautious analyst commentary is drawing attention to how market opinion is evolving around AtriCure’s longer-term prospects. We’ll now examine how AtriCure’s strong quarterly revenue performance interacts with shifting analyst sentiment to reshape its existing...

Insiders who purchased US$4.20m worth of Nomadar Corp. ( NASDAQ:NOMA ) shares over the past year recouped some of their...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

TOYO Co., Ltd. ( NASDAQ:TOYO ), might not be a large cap stock, but it led the NASDAQCM gainers with a relatively large...

Why Phreesia’s latest guidance cut matters for investors Phreesia (PHR) has drawn fresh attention after issuing lower fiscal 2027 revenue guidance, tying the reset to weaker spending from pharmaceutical clients. The announcement triggered a sharp share price drop and several analyst downgrades. See our latest analysis for Phreesia. The lowered fiscal 2027 revenue outlook, combined with mixed fourth quarter results and analyst downgrades, has sharply shifted sentiment. A 7 day share price...